Vijay Gunuganti, MD
Medical Oncology · San Antonio, TXNPI 1073535076
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,241,995 of the $1,516,002 with a category attached, or 81.9%. 59 manufacturers reported payments, led by Johnson & Johnson at 35.3% of the total. 2025 is the largest year on record at $333,757, 2.9 times the $116,651 reported in 2019. Among medical oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,487 payments — averaging $1019.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$536K
- E.r. Squibb & Sons, L.L.C.$323K
- Bayer$235K
- AstraZeneca$87K
- Amgen$85K
- Regeneron Healthcare Solutions, Inc.$71K
- plus $179K from 53 others
Across 463 payments — averaging $1428.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$285K
- E.r. Squibb & Sons, L.L.C.$128K
- AstraZeneca$104K
- Astrazeneca UK Limited$92K
- GSK$50K
- Merck$3K
What the payments were for
- Consulting fees$136,2519%
- Speaking & faculty fees$1,241,99582%
- Travel & lodging$94,3286%
- Food & beverage$42,9363%
- Education$4920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,516,002 in reported general payments places this provider in the 95th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 37 | $575,477 |
| Lenalidomide | 36 | $315,101 |
| FotivdaTivozanib Hcl | 12 | $262,200 |
| ErleadaApalutamide | 14 | $235,021 |
| NubeqaDarolutamide | 17 | $201,475 |
| NinlaroIxazomib Citrate | 12 | $151,353 |
| AustedoDeutetrabenazine | 15 | $81,918 |
| VenclextaVenetoclax | 11 | $73,868 |
| XareltoRivaroxaban | 107 | $48,012 |
| EliquisApixaban | 106 | $40,558 |
| EntrestoSacubitril/Valsartan | 34 | $11,737 |
| TradjentaLinagliptin | 32 | $9,320 |
| JardianceEmpagliflozin | 23 | $8,121 |
| GemtesaVibegron | 24 | $5,823 |
| MyrbetriqMirabegron | 19 | $5,578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $2,165 | $575,47737 claims |
| Johnson & JohnsonErleada, Xarelto | $535,669 | $283,033121 claims |
| BayerNubeqa | $235,121 | $201,47517 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $51,402 | $151,35312 claims |
| AbbVieVenclexta | $250 | $73,86811 claims |
| PfizerEliquis | $11,218 | $40,558106 claims |
| Boehringer IngelheimTradjenta, Jardiance | $83 | $17,44155 claims |
| NovartisEntresto | $6,907 | $11,73734 claims |
| AstraZenecaBrilinta, Farxiga | $87,402 | $8,02434 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $91 | $5,82324 claims |
| Astellas Pharma US IncMyrbetriq | $3,329 | $5,57819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 495 medical oncology providers in Texas.
Other medical oncology in San Antonio
- Virginia KaklamaniSan Antonio$787K
- John SarantopoulosSan Antonio$588K
- Sukeshi AroraSan Antonio$188K
- Anthony TolcherSan Antonio$125K
- Zohra NooruddinSan Antonio$113K
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.